Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19

Cancer Clinical Trial

Official title:

Exercise Therapy in Cancer Patients Hospitalized for COVID-19: A Digitized Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04824443
• Other study ID #: 21-101
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 29, 2021
• Est. completion date: March 29, 2025

Study information

• Verified date: May 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and tolerability of a 30-week aerobic exercise therapy program in cancer patients recovering from COVID-19. The study will look at whether the aerobic exercise therapy causes few or mild side effects in participants. Aerobic exercise is physical activity that uses the large muscle groups (muscles in your legs, buttocks, back, and chest) and can be performed for several minutes at a time. The aerobic exercise therapy being used in this study will be a walking program that will be adjusted so it matches participant fitness levels (how much exercise you can handle).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3
• Est. completion date: March 29, 2025
• Est. primary completion date: March 29, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18

• Previously admitted to a hospital for Covid-19

• Discharged from hospital for at least 30 days

• Previously treated for cancer at MSK

• Interval of = 12 months but = 10 years following completion of primary non-hormonal anti-cancer therapy (current endocrine therapy and maintenance therapy allowed)

• Space to house a treadmill at personal residence

• Cleared for exercise participation as per screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+)

• Performing less than 90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self-report

• If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study.

• Women <50 years old who are of child-bearing potential must have a negative pregnancy test within 14 days of enrollment.

Exclusion Criteria:

• Currently receiving home oxygen after discharge

• Enrollment onto any other interventional investigational study

• Current treatment for any other diagnosis of invasive cancer of any kind

• Distant metastatic malignancy of any kind

• Receiving non-hormonal anticancer therapy

• Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Related Conditions & MeSH terms

• Cancer
• Coronavirus
• Coronavirus Infections
• COVID-19
• Covid19

Intervention

Other:
• Aerobic Exercise Therapy
Aerobic Exercise Therapy/AT will consist of 30 weeks of treadmill walking sessions. AT will consist of supervised, individualized walking delivered up to 6 times weekly (over a 7-day period) to achieve a cumulative total duration ranging from 90 mins/wk up to 375 mins/wk following a non-linear dosing schedule. The planned dose and scheduling of AT will be continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period (i.e., non-linear periodized schedule).

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Limited protocol activities)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	New York
United States	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of serious adverse events during study-related assessments	Safety will be evaluated by the frequency of serious (i.e., life-threatening, hospitalization, significant incapacity, important medical events) adverse events during study-related assessments and exercise sessions according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.	30 weeks

External Links

•   Memorial Sloan Kettering Cancer Center